Next-generation obesity drugs in focus at upcoming diabetes meeting, Berenberg says

Berenberg analysts outline expectations for obesity drug updates during American Diabetes Association meeting on June 20-23

Investor interest in obesity stocks waned after Novo Nordisk's NOVOb.CO CagriSema disappointed, but event could revive it with new data - Berenberg

Adds, Eli Lilly's LLY.N orforglipron also in spotlight

Detailed CagriSema data can highlight weight loss potential and other parameters that could help Novo move further off its lows, they say

YTD, NOVOb is down 16.7%

Adds, if orforglipron confirmed safe, will increase investor confidence of a 2026 launch

Several companies to present data on amylin, and if positive, Berenberg expects a positive effect for Zealand ZELA.CO due to its high exposure

Data on Amgen's AMGN.O MariTide, Lilly's bimagrumab and Roche's ROG.S CT-388 are also on Berenberg's radar

It will also watch updates from BrightGene 688166.SS on BGM0504, Lilly/Innovent on mazdutide in diabetes and Terns Pharma TERN.O on oral GLP-1, TERN-601